Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | December 11, 2012 | December 13, 2012 |
| AbbVie Inc.ABBV · Entity 2800 | Vice Chairman | February 25, 2022 | March 01, 2022 |
| CrowdStrike Holdings, Inc.CRWD · Entity 1172 | Director | September 18, 2026 | September 22, 2026 |
| GENERAL DYNAMICS CORPGD · Entity 2916 | Director | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 11, 2012 · Filed December 13, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 179,338 |
Ending reported balance
After 2012-12-11 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2012-12-11 · Exercise / conversion · Acquired 36,985 · Balance 216,323 Row 2 · 2012-12-11 · Exercise / conversion · Acquired 67,200 · Balance 283,523 Row 3 · 2012-12-11 · Exercise / conversion · Acquired 1,045 · Balance 284,568 Row 4 · 2012-12-11 · Exercise / conversion · Acquired 2,395 · Balance 286,963 Row 5 · 2012-12-11 · Exercise / conversion · Acquired 652 · Balance 287,615 Row 6 · 2012-12-11 · Exercise / conversion · Acquired 11,500 · Balance 299,115 Row 7 · 2012-12-11 · Sale · Disposed 119,777 · Balance 179,338 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.34 · Expires 2015-02-17 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2012-12-11 · Exercise / conversion · Disposed 36,985 · Balance 0 F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.54 · Expires 2017-02-15 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2012-12-11 · Exercise / conversion · Disposed 67,200 · Balance 0 F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.16 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2012-12-11 · Exercise / conversion · Disposed 1,045 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.74 · Expires 2014-02-19 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2012-12-11 · Exercise / conversion · Disposed 2,395 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.01 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2012-12-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2012-12-11 · Exercise / conversion · Disposed 652 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.60 · Expires 2021-02-17 | Direct | 38,333 |
Reported balance
After 2012-12-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2012-12-11 · Exercise / conversion · Disposed 11,500 · Balance 38,333 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Employee stock option granted pursuant to Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.
F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date February 25, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 248,002 |
Reported balance
After 2022-02-25 transaction · row 1
1 source rowRow 1 · 2022-02-25 · Tax withholding · Disposed 40,490 · Balance 248,002 |
CrowdStrike Holdings, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 38,724 |
Reported balance
After 2026-09-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-18 · Grant · Acquired 68 · Balance 38,724 F1: The shares represent fully vested RSUs issued in lieu of quarterly cash retainer(s) payable under the issuer's Outsider Director Compensation Policy. The RSUs immediately converted into shares of the issuer's Class A Common Stock. F2: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock. F3: Includes shares to be issued in connection with the vesting of one or more RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares represent fully vested RSUs issued in lieu of quarterly cash retainer(s) payable under the issuer's Outsider Director Compensation Policy. The RSUs immediately converted into shares of the issuer's Class A Common Stock.
F2: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock.
F3: Includes shares to be issued in connection with the vesting of one or more RSUs.
GENERAL DYNAMICS CORP
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,792 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 105 · Balance 13,792 F1: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects stock received in lieu of director fees in accordance with outside directors' compensation program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $62.69 | $31,343.75 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,552 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $62.68 | $37,608.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,052 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,000 | $62.67 | $188,010.00 |
DisclosureSEC source: 0001179110-12-010603 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,652 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 3,611 | $0.00 Strike: $62.50 | $0.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · derivative · entry 34 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,611 Underlying: Common shares · 3,611 shares Expires 2013-02-13 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. F4 · security: A transfer of stock options for 213,752 Abbott Shares that was exempt from Section 16 also occurred. Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 49,800 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · derivative · entry 33 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 49,800 shares Expires 2006-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program,in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,131 | $0.00 Strike: $49.08 | $0.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · derivative · entry 32 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 4,131 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,158 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · derivative · entry 31 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,158 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program,in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.67 | $6,266.75 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 30 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,652 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,200 | $62.66 | $137,852.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 29 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,752 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.66 | $6,265.50 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 28 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,952 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,000 | $62.65 | $187,950.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 27 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,052 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $62.65 | $25,058.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 26 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,052 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $62.64 | $119,016.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 25 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,452 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.64 | $12,527.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 24 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,352 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $62.63 | $75,156.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 23 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,552 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $62.63 | $31,312.50 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 22 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,752 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,800 | $62.62 | $112,716.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 21 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,252 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $62.62 | $56,353.50 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 20 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,052 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,400 | $62.61 | $275,484.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 19 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,952 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.61 | $6,260.60 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 18 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,352 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $62.61 | $75,126.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 17 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,452 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $62.60 | $125,200.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 16 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,652 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.60 | $6,259.75 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 15 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,652 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $62.60 | $37,557.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 14 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,752 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $62.59 | $125,180.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 13 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,352 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.59 | $6,258.75 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 12 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,352 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $62.59 | $37,551.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 11 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,452 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $62.58 | $56,322.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 10 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,052 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.58 | $12,515.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 9 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,952 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $62.57 | $31,285.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 8 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,152 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $62.56 | $25,024.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 7 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,652 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $62.56 | $37,533.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,052 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $62.55 | $18,765.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,652 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,211 | $62.50 | $325,687.50 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,952 Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 49,800 | $44.16 | $2,199,168.00 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,131 | $49.08 | $202,749.48 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2012 Filed Jun 20, 2012 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,158 | $46.34 | $100,001.72 |
DisclosureSEC source: 0001179110-12-010602 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the transfer of 19,604 Abbott common shares that was exempt from Section 16. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 17,452 | $57.04 | $995,462.08 |
DisclosureSEC source: 0001179110-12-004074 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,678 Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 79,800 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003236 · edgar.xml · derivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,800 Underlying: Common shares · 79,800 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,600 on 02/17/2013, 26,600 on 02/17/2014, and 26,600 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 44,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003236 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,130 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 14,363 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-11-016151 · edgar.xml · derivative · entry 8 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 14,363 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,500 | $54.60 | $464,100.00 |
DisclosureSEC source: 0001179110-11-016151 · edgar.xml · nonDerivative · entry 7 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,930 Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,510 | $54.60 | $137,048.51 |
DisclosureSEC source: 0001179110-11-016151 · edgar.xml · nonDerivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,430 Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,232 | $54.61 | $67,279.52 |
DisclosureSEC source: 0001179110-11-016151 · edgar.xml · nonDerivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,940 Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.61 | $5,461.06 |
DisclosureSEC source: 0001179110-11-016151 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,172 Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,254 | $54.62 | $68,493.48 |
DisclosureSEC source: 0001179110-11-016151 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,272 Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 767 | $54.63 | $41,901.21 |
DisclosureSEC source: 0001179110-11-016151 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,526 Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 14,363 | $53.63 | $770,215.88 |
DisclosureSEC source: 0001179110-11-016151 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 700 | $47.99 | $33,593.00 |
DisclosureSEC source: 0001179110-11-003922 · edgar.xml · nonDerivative · entry 30 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,330 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $47.99 | $23,992.50 |
DisclosureSEC source: 0001179110-11-003922 · edgar.xml · nonDerivative · entry 29 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,030 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.